The Thoracic Oncology Unit of the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan is a clinical and translational research unit dedicated to the diagnosis and treatment of thoracic malignancies, with a particular focus on lung cancer, mesothelioma, and thymic tumors. The mission of the team is to offer personalized care pathways based on innovative and integrated therapeutic approaches through a highly specialized and research-oriented multidisciplinary model.
The clinical activity is structured as follows:
- Weekly outpatient clinics for first oncological consultations, dedicated to the initial assessment and management of new patients;
- Weekly follow-up clinics, for the monitoring of patients undergoing treatment or in surveillance;
- Daily clinics for the administration of oral and intravenous therapies, both standard and experimental, within active clinical trials;
- A dedicated clinic for thymic tumors, providing specialized clinical and therapeutic management.
The unit is an active part of the thoracic multidisciplinary team, which coordinates:
- Multidisciplinary consultations for undiagnosed patients, within the CAT (Cancer Accession Team) clinic, for suspected lung cancer cases;
- Multidisciplinary case discussions for diagnosed patients, requiring a multimodal therapeutic strategy involving surgery, radiotherapy, oncology, and pulmonology.
Clinical and translational research is a core component of the unit, with active participation in phase I, II, and III clinical trials for lung cancer, mesothelioma, and thymic tumors. In addition, observational studies are conducted to better understand the biology and evolution of these diseases, with a particular focus on identifying predictive biomarkers, mechanisms of resistance to immunotherapy, and strategies for personalized treatment.
To schedule a first oncological consultation for thoracic malignancies through the National Health Service (SSN), patients can contact the CUP (Unified Booking Center) at +39 0223901, or book directly at the front desks of the Fondazione IRCCS Istituto Nazionale dei Tumori.
First oncological consultations are available on the following days and times:
- Tuesday afternoon from 2:00 PM to 5:00 PM
- Wednesday morning from 9:00 AM to 11:00 AM
- Friday morning from 9:00 AM to 11:00 AM
Patients are advised to bring all relevant medical documentation (e.g., radiological images, histological reports, blood tests, previous specialist opinions) to allow for a comprehensive assessment during the first visit.
Thoracic oncology consultations are provided promptly through the SSN. For those who prefer, the option of private consultations is also available.
- Mail: segreteria.oncologiamedica@istitutotumori.mi.it
- Mail: segreteria.om1@istitutotumori.mi.it
- Tel: 0223903066
- Tel: 0223903650
From Monday to Friday, from 9.00 AM to 5.00 PM.
Access hours for scientific representatives: by appointment.
Prof. De Braud Filippo
Head
Dott.ssa Beninato Teresa
Medical Director
Dott.ssa Brambilla Marta
Medical Director
Dott. Lo Russo Giuseppe
Medical Director
Dott.ssa Mazzeo Laura
Medical Director
Dott. Occhipinti Mario
Medical Director
Dott.ssa Prelaj Arsela
Medical Director
Dott.ssa Proto Claudia
Medical Director
Dott.ssa Corrao Giulia
Professional Collaborator
Dott. Meazza Prina Marco
Professional Collaborator
Medico in formazione specialistica:
Dott. Paolo Ambrosini
Dott.ssa Giorgia Di Liberti
Dott.ssa Marta De Ponti
Dott.ssa Daniela Miliziano
Dott.ssa Giulia Montelatici
Dott. Stefano Natangelo
Ricercatrice senior:
Dott.ssa Monica Ganzinelli
Infermiera di ricerca:
Dott.ssa Andra Diana Dumitrascu
Case Manager:
Dott.ssa Miriam Monica Fink
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation du
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearra
A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non--Small Cell Lung Cancer
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locall
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinu
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab
Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV o
A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator- Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stag
A phase Ib/II, open-label, multicentric study evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metas
A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination with Other Anticancer Agents in Participants with
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non–Small Cell Lung Cancer
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced o
A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with pr
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomi
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator- Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Part
Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients: the Ark clinical trial
Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NS
SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First- Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizum
Cancer Cell-Intrinsic PD-1 and immune-microenvironment boost tumor growth upon immune-checkpoint inhibitors in NSCLC
Last update: 22/07/2025